Chow, L. Q. M., Eckhardt, S. G., O’Bryant, C. L., Schultz, M. K., Morrow, M., Grolnic, S., . . . Gore, L. (2007). A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.

Chow, Laura Q. M., S. Gail Eckhardt, Cindy L. O’Bryant, Mary Kay Schultz, Mark Morrow, Stacy Grolnic, Michele Basche, and Lia Gore. A Phase I Safety, Pharmacological, and Biological Study of the Farnesyl Protein Transferase Inhibitor, Lonafarnib (SCH 663366), in Combination With Cisplatin and Gemcitabine in Patients With Advanced Solid Tumors. 2007.

Chow, Laura Q. M., et al. A Phase I Safety, Pharmacological, and Biological Study of the Farnesyl Protein Transferase Inhibitor, Lonafarnib (SCH 663366), in Combination With Cisplatin and Gemcitabine in Patients With Advanced Solid Tumors. 2007.